Aaron Deykin, M.D.

Aaron Deykin, M.D.

Chief Medical Officer and Head of Research and DevelopmentatUpstream Bio· In the 2025 proxy

Pay in FY2025Upstream Bio stock +65.1% the same year

Aaron Deykin, M.D. was paid $1.8M in FY2025 (Dec). Upstream Bio stock rose 65.1% that year.

Pay$100 in the stock at the end of FY24 → $165
Pay is from the Summary Compensation Table of each Upstream Bio proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Upstream BioPublic company · 1 yr
    • Chief Medical Officer and Head of Research and Development2025 – Present · 1 yrStock in role -85%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?